

Applicant: Woodward
Serial No.: 09/847,935
Filed: May 3, 2001
Page 2 of 17

Sub
C1
36. (Amended) A composition comprising

a therapeutic component in a therapeutically effective amount, and

C1
an efficacy enhancing component in an effective amount to enhance the pharmacokinetic disposition of the therapeutic component and to enhance the movement of the therapeutic component across a lipid membrane, or a biological membrane under physiological conditions, the efficacy enhancing component being present in a complex with the therapeutic component and being selected from the group consisting of anionic polymers, fatty acids, and mixtures thereof, the complex remaining substantially intact in an aqueous environment, each of enhanced effects being relative to the effect obtained with the therapeutic component without the efficacy enhancing component.

C2
40. (Amended) A composition of claim 39 wherein the quinoxaline component is selected from the group consisting of quinoxaline, (2-imidazolyl-2-ylamino) quinoxaline, 5-bromo-6-(2-imidazolyl-2-ylamino) quinoxaline, and quinoxaline derivatives mixtures thereof.

41. (Amended) A composition of claim 36 wherein the therapeutic component is selected from the group consisting of NMDA antagonists, antibacterials, antihistamines, decongestants, antiinflammatories, antiparasitics, miotics, anticholinergics, adrenergics, antivirals, local anesthetics, antifungals, amoebicidals, trichomonocidals, analgesics, mydriatics, antiglaucoma drugs, carbonic anhydrase inhibitors, ophthalmic diagnostic agents, ophthalmic agents used as adjuvants in

BEST AVAILABLE COPY

Applicant: Woodward
Serial No.: 09/847,935
Filed: May 3, 2001
Page 3 of 17

surgery, chelating agents, antineoplastics, antihypertensives, muscle relaxants, diagnostics, and mixtures thereof.

43. (Amended) A composition of claim 36 wherein the efficacy enhancing component is selected from the group consisting of saturated fatty acids and unsaturated fatty acids, and mixtures thereof.

C2
conceded.
44. (Amended) A composition of claim 36 wherein the efficacy enhancing component comprises a fatty acid with more than 12 carbon atoms per molecule.

45. (Amended) A composition of claim 36 wherein the efficacy enhancing component comprises a docosahexanoic acid.

46. (Amended) A composition of claim 36 wherein the efficacy enhancing component comprises a linolenic acid.

C3
48. (Amended) A composition of claim 36 wherein the efficacy enhancing component is therapeutically active when complexed with the therapeutic component.

49. (Amended) A composition of claim 36 wherein the efficacy enhancing component is therapeutically active when the efficacy enhancing component is not complexed with the therapeutic component.

C4
51. (Amended) A composition of claim 36 wherein the efficacy enhancing component comprises a prostanoid.

BEST AVAILABLE COPY

Applicant: Woodward
Serial No.: 09/847,935
Filed: May 3, 2001
Page 4 of 17

52. (Amended) A composition of claim 36 wherein the therapeutic component comprises a 5-bromo-6-(2-imidazolyl-2-ylamino) quinoxaline,

*C4
cancel*
the efficacy enhancing component is selected from the group consisting of docosahexanoic acids, linolenic acids, prostanoids, and mixtures thereof; and

the efficacy enhancing component enhances the movement of the therapeutic component across a biological membrane under physiological conditions.

53. (Amended) A composition of claim 36 wherein the complex is insoluble.

59. (Amended) A composition comprising:

an adrenergic agonist; and

a fatty acid selected from the group consisting of docosahexanoic acids, linolenic acids, and mixtures thereof,

C5
wherein the adrenergic agonist is present in a complex with the fatty acid, the complex substantially remains intact in an aqueous environment.

60. (Amended) A composition comprising a complex and a carrier component, the complex comprising:

a therapeutic component, and

an efficacy enhancing component,

wherein the efficacy enhancing component is selected from the group consisting of anionic polymers, fatty acids, and mixtures thereof, and is present in an amount effective to enhance the movement of the therapeutic component across a lipid membrane, or a biological membrane under physiological

BEST AVAILABLE COPY

Applicant: Woodward
Serial No.: 09/847,935
Filed: May 3, 2001
Page 5 of 17

C5
conced

conditions, each of the enhanced effects being relative to the effect obtained with the therapeutic component without the efficacy enhancing component.

63. (Amended) A composition of claim 62 wherein the quinoxaline component is selected from the group consisting of quinoxaline, (2-imidazolyl-2-ylamino) quinoxaline, 5-bromo-6-(2-imidazolyl-2-ylamino) quinoxaline, quinoxaline derivatives and mixtures thereof.

C6

64. (Amended) The composition of claim 60 wherein the therapeutic component is selected from the group consisting of NMDA antagonists, antibacterials, antihistamines, decongestants, antiinflammatories, antiparasitics, miotics, anticholinergics, adrenergics, antivirals, local anesthetics, antifungals, amoebicidals, trichomonocidals, analgesics, mydriatics, antiglaucoma drugs, carbonic anhydrase inhibitors, ophthalmic diagnostic agents, ophthalmic agents used as adjuvants in surgery, chelating agents, antineoplastics, antihypertensives, muscle relaxants, diagnostics, and mixtures thereof.

Please add the following claim:

C7

69. (New) A composition comprising:

a therapeutic component in a therapeutically effective amount, and

an efficacy enhancing component in an effective amount to enhance the pharmacokinetic disposition of the therapeutic component and to enhance the movement of the therapeutic component across a lipid membrane, or a biological membrane

BEST AVAILABLE COPY